179 related articles for article (PubMed ID: 31266833)
1. Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.
Dylgjeri E; McNair C; Goodwin JF; Raymon HK; McCue PA; Shafi AA; Leiby BE; de Leeuw R; Kothari V; McCann JJ; Mandigo AC; Chand SN; Schiewer MJ; Brand LJ; Vasilevskaya I; Gordon N; Laufer TS; Gomella LG; Lallas CD; Trabulsi EJ; Feng FY; Filvaroff EH; Hege K; Rathkopf D; Knudsen KE
Clin Cancer Res; 2019 Sep; 25(18):5623-5637. PubMed ID: 31266833
[TBL] [Abstract][Full Text] [Related]
2. DNA-PK, Nuclear mTOR, and the Androgen Pathway in Prostate Cancer.
Giguère V
Trends Cancer; 2020 Apr; 6(4):337-347. PubMed ID: 32209447
[TBL] [Abstract][Full Text] [Related]
3. A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer.
Dylgjeri E; Kothari V; Shafi AA; Semenova G; Gallagher PT; Guan YF; Pang A; Goodwin JF; Irani S; McCann JJ; Mandigo AC; Chand S; McNair CM; Vasilevskaya I; Schiewer MJ; Lallas CD; McCue PA; Gomella LG; Seifert EL; Carroll JS; Butler LM; Holst J; Kelly WK; Knudsen KE
Clin Cancer Res; 2022 Apr; 28(7):1446-1459. PubMed ID: 35078861
[TBL] [Abstract][Full Text] [Related]
4. Beyond DNA repair: DNA-PK function in cancer.
Goodwin JF; Knudsen KE
Cancer Discov; 2014 Oct; 4(10):1126-39. PubMed ID: 25168287
[TBL] [Abstract][Full Text] [Related]
5. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.
Sun H; Mediwala SN; Szafran AT; Mancini MA; Marcelli M
Horm Cancer; 2016 Jun; 7(3):196-210. PubMed ID: 26957440
[TBL] [Abstract][Full Text] [Related]
6. The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells.
Palomera-Sanchez Z; Watson GW; Wong CP; Beaver LM; Williams DE; Dashwood RH; Ho E
J Nutr Biochem; 2017 Sep; 47():113-119. PubMed ID: 28582660
[TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation.
Yin Y; Li R; Xu K; Ding S; Li J; Baek G; Ramanand SG; Ding S; Liu Z; Gao Y; Kanchwala MS; Li X; Hutchinson R; Liu X; Woldu SL; Xing C; Desai NB; Feng FY; Burma S; de Bono JS; Dehm SM; Mani RS; Chen BPC; Raj GV
Cancer Res; 2017 Sep; 77(18):4745-4754. PubMed ID: 28754673
[TBL] [Abstract][Full Text] [Related]
8. A hormone-DNA repair circuit governs the response to genotoxic insult.
Goodwin JF; Schiewer MJ; Dean JL; Schrecengost RS; de Leeuw R; Han S; Ma T; Den RB; Dicker AP; Feng FY; Knudsen KE
Cancer Discov; 2013 Nov; 3(11):1254-71. PubMed ID: 24027197
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Zenke FT; Zimmermann A; Sirrenberg C; Dahmen H; Kirkin V; Pehl U; Grombacher T; Wilm C; Fuchss T; Amendt C; Vassilev LT; Blaukat A
Mol Cancer Ther; 2020 May; 19(5):1091-1101. PubMed ID: 32220971
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells.
Azad A; Jackson S; Cullinane C; Natoli A; Neilsen PM; Callen DF; Maira SM; Hackl W; McArthur GA; Solomon B
Mol Cancer Res; 2011 Dec; 9(12):1696-707. PubMed ID: 22009179
[TBL] [Abstract][Full Text] [Related]
11. DNA-PKcs: A Targetable Protumorigenic Protein Kinase.
Dylgjeri E; Knudsen KE
Cancer Res; 2022 Feb; 82(4):523-533. PubMed ID: 34893509
[TBL] [Abstract][Full Text] [Related]
12. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
13. DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.
Kothari V; Goodwin JF; Zhao SG; Drake JM; Yin Y; Chang SL; Evans JR; Wilder-Romans K; Gabbara K; Dylgjeri E; Chou J; Sun G; Tomlins SA; Mehra R; Hege K; Filvaroff EH; Schaeffer EM; Karnes RJ; Quigley DA; Rathkopf DE; He HH; Speers C; Spratt DE; Gilbert LA; Ashworth A; Chinnaiyan AM; Raj GV; Knudsen KE; Feng FY
Clin Cancer Res; 2019 Sep; 25(18):5608-5622. PubMed ID: 31266829
[TBL] [Abstract][Full Text] [Related]
14. BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.
Berger M; Wortmann L; Buchgraber P; Lücking U; Zitzmann-Kolbe S; Wengner AM; Bader B; Bömer U; Briem H; Eis K; Rehwinkel H; Bartels F; Moosmayer D; Eberspächer U; Lienau P; Hammer S; Schatz CA; Wang Q; Wang Q; Mumberg D; Nising CF; Siemeister G
J Med Chem; 2021 Sep; 64(17):12723-12737. PubMed ID: 34428039
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
16. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
17. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
[TBL] [Abstract][Full Text] [Related]
18. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
Sugawara T; Baumgart SJ; Nevedomskaya E; Reichert K; Steuber H; Lejeune P; Mumberg D; Haendler B
Int J Cancer; 2019 Sep; 145(5):1382-1394. PubMed ID: 30828788
[TBL] [Abstract][Full Text] [Related]
19. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
[TBL] [Abstract][Full Text] [Related]
20. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
